# Firmonertinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/firmonertinib

> The next catalyst for firmonertinib, sponsored by ArriVent BioPharma, Inc. (AVBP), is its primary completion, February 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | firmonertinib |
| Codes | AST2818 |
| Sponsor | ArriVent BioPharma, Inc. (AVBP) https://sec-api.dev/companies/avbp/catalysts |
| Indications | classical egfr mutations, [Non-Small-Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer) |
| Modality | small_molecule |
| FDA designations | accelerated, breakthrough, fast track, orphan |

## Timeline

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-03, last confirmed 2025-03-03.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002002): "In March 2024, ArriVent's clinical collaboration partner Beijing InnoCare Pharma Tech Co., Ltd., dosed the first patient in the Phase 1b combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations." https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303xex99d1.htm

### Q4 2024: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: classical EGFR mutations.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015622): "Initiation of dose expansion cohort for the ongoing Phase 1b trial evaluating firmonertinib in combination with SHP2 inhibitor ICP-189 by InnoCare in patients with classical EGFR mutations expected in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114xex99d1.htm

### 2025: topline data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2024-11-14, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007259): "We expect topline data in 2025 in our event-driven global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations."" https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007259): "ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and expects to provide an update on timing of the topline Phase 3 data release in Q2 2025." https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015622): "Firmonertinib is currently being studied as a monotherapy in the pivotal, global Phase 3 FURVENT trial (NCT05607550) evaluating firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations with topline data expected in 2025." https://www.sec.gov/Archives/edgar/data/1868279/000155837024015622/avbp-20241114xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001999): "We are currently conducting our FURVENT clinical trial, a global, pivotal Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations and we expect topline data in 2025." https://www.sec.gov/Archives/edgar/data/1868279/000155837025001999/avbp-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002002): "ArriVent anticipates having top-line data in 2025 and expects to provide an update on timing of the top-line Phase 3 data release in Q2 2025." https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001999): "We have completed enrollment in our global, pivotal Phase 3 FURVENT clinical trial in first-line non-squamous locally advanced or metastatic EGFRm NSCLC patients with exon 20 insertion mutations and we expect topline data from this clinical trial in 2025." https://www.sec.gov/Archives/edgar/data/1868279/000155837025001999/avbp-20241231x10k.htm

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-03-05, last confirmed 2026-03-05.
- SEC Form 10-K (accession 0001104659-26-024127): "In December 2025, we announced the first patient dosed and plan to enroll 480 patients in ALPACCA, a global, pivotal Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations being conducted jointly with Allist." https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/avbp-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-024127): "We have initiated our pivotal Phase 3 ALPACCA study with our first patient dosed in December 2025." https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/avbp-20251231x10k.htm

### early 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-09-09, last confirmed 2025-09-09.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011954): "Topline data expected in early 2026." https://www.sec.gov/Archives/edgar/data/1868279/000155837025011954/avbp-20250909xex99d1.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-07-21, last confirmed 2026-08-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-094869): "Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026" https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058638): "Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026" https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058638): ""Our two ongoing pivotal firmonertinib trials in uncommon EGFR-mutant non-small cell lung cancer (NSCLC) continue to advance, with topline monotherapy data for frontline EGFR exon 20 insertion mutations expected in mid-2026 and our global Phase 3 pivotal ALPACCA study continuing to enroll patients globally," said Bing Yao, CEO of ArriVent." https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058638): "Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is projected to be in mid-2026." https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-024112): "Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026" https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-024112): "Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertions mutant NSCLC is projected to be in mid-2026." https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-108839): "Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is projected to be in early 2026." https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/avbp-20251110xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010974): "Top-line firmonertinib monotherapy data from global pivotal FURVENT Phase 3 study for first-line EGFR exon20 insertion mutant NSCLC projected to be in early 2026" https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010974): "Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR Exon 20 insertions mutant NSCLC is projected to be in early 2026." https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-069169): "PA, July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be in early 2026." https://www.sec.gov/Archives/edgar/data/1868279/000110465925069169/tm2521271d1_ex99-1.htm
- SEC Form 10-K (accession 0001104659-26-024127): "We are currently awaiting topline data from our FURVENT clinical trial, a global, pivotal Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations and we expect topline data in mid-2026." https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/avbp-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-094869): "Top-line data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is anticipated in 2H 2026." https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm

### February 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07185997 (Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor ArriVent BioPharma, Inc.." https://clinicaltrials.gov/study/NCT07185997

### Feb to May 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07185997 (Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor ArriVent BioPharma, Inc.." https://clinicaltrials.gov/study/NCT07185997

## Same indication

- [Cab-axl-adc](https://sec-api.dev/pdufa/cab-axl-adc) (BCAB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/firmonertinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Firmonertinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/firmonertinib

```bibtex
@misc{secapidev_pdufa_firmonertinib_20261116,
  title        = {Firmonertinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/firmonertinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_firmonertinib_20261116","title":"Firmonertinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/firmonertinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
